Arthritis Clinical Trials in San Antonio
View 29 new treatments for Arthritis in San Antonio, TX. Every day, Power helps hundreds of Arthritis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Voltaren Gel for Knee Osteoarthritis Pain
HALEON Clinic, San Antonio + 1 more
The purpose of this study is to investigate how topical diclofenac use can improve functional mobility and physical activity primarily, as well as other quality-of-life (QoL) parameters such as sleep, mood, and engagement in daily activities in participants with knee OA.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis
Eli Lilly Clinic, San Antonio + 3 more
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Baricitinib for Rheumatoid Arthritis
Eli Lilly Clinic, San Antonio + 2 more
This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
TG-C for Knee Osteoarthritis
Kolon TissueGene Clinic, San Antonio + 2 more
This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
David W Romness, MD
Principal Investigator
Tildrakizumab for Psoriatic Arthritis
Sun Clinic, San Antonio + 1 more
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Tildrakizumab SC Injection for Psoriatic Arthritis
Sun Clinic, San Antonio + 2 more
An open label phase 3 study
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Secukinumab for Polymyalgia Rheumatica
Novartis Clinic, San Antonio + 1 more
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Novartis Pharmaceuticals
Study Director
RTX-GRT7039 Injections for Knee Osteoarthritis
Grünenthal Clinic, San Antonio + 1 more
This trial uses knee injections called RTX-GRT7039 for patients with knee osteoarthritis who still have pain despite usual treatments. The injections aim to reduce knee pain, possibly by affecting pain pathways or inflammation.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Retatrutide for Obesity
Eli Lilly Clinic, San Antonio + 1 more
This trial is testing a weekly medication called retatrutide. It aims to help people who are overweight or obese and have knee osteoarthritis. The study will last over a year to see if the medication is safe and effective.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Tc 99m Tilmanocept Imaging for Rheumatoid Arthritis
Navidea Biopharmaceuticals Clinic, San Antonio + 1 more
This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Michael Blue, MD
Study Director
Page 1 of 4
Frequently Asked Questions
Explore related conditions